Immunoscore® Assays & Biopharma Services
Immunoscore for clinicians
Immunoscore® is an in vitro diagnostic test which measures the host immune response at the tumor site. It provides a robust, quantitative and standardized assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications.
In Localized Colon Cancer, Immunoscore is used in addition to TNM classification. It refines the patient’s risk profile and guides the oncologists in their treatment decision.
Recently, Immunoscore® was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer and Immune response is now considered as an essential and desirable diagnostic criterion for colorectal cancer by World Health Organization (WHO).
How to get access to the test?
Performed in our HalioDx CLIA lab and available in more than 25 countries.
To know more : infos@haliodx.com or https://www.immunoscore-colon.com/for-healthcare-professionals/
~
Biopharma Services
HalioDx Biopharma programs provide biotech and pharma research teams with cutting edge immune-based diagnostic products and solutions to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or CDx tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling platforms, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and US to develop, manufacture, register and market in vitro diagnostic (IVD) products....
More Info Less Info